What became of HHC wholesale — an assessment for traders

For about two years HHC was a market of its own: in 2022 it appeared on a large scale in European trade, and by 2024 it was finished in Germany. Anyone who was buying at the time knows the pattern — and that is precisely the subject here, because it is repeating itself.

How the market came about

HHC is a hydrogenation product. It is obtained from CBD or THC, and initially it fell under none of the relevant lists. This gap was the entire business rationale: not a particular quality, but a substance that nobody had covered yet.

Such gaps have a short half-life. The legislator reacts, and since 2024 it no longer reacts with individual entries but with structural clauses: what is covered is a chemical core structure together with its derivatives. The next variant therefore falls under the ban as soon as it appears.

What applies in Germany

HHC is listed by name in Anlage II zum Betäubungsmittelgesetz. Handling it — and that includes purchasing, storage and resale — requires a licence under § 3 BtMG. Anyone who trades without one is operating in criminal law, not in administrative-offence law.

The entry does provide for an exception: for a non-synthetic form that is on the market for non-medical purposes. In practice this exception does not support trade. Commercially available HHC is produced by hydrogenation from CBD or THC — it is therefore precisely not non-synthetic. Anyone wishing to rely on the exception must be able to document the origin without gaps; for hydrogenated goods this proof cannot, in our assessment, be furnished.

For wholesale this simply means: no HHC without a § 3 licence. A batch with a clean certificate of analysis does not change that, because the certificate documents the content and not the licence.

The lesson for the next abbreviation

When a supplier offers you a new cannabinoid as “not yet covered”, three questions are decisive — and all three can be clarified before the purchase:

• Which structural class? Not: is the name on a list. But rather: does the molecule fall under a generic clause. For the dibenzopyran derivatives, in Germany that is number 2.3 of NpSG-Anlage 1.
• Which production route? Goods obtained semi-synthetically regularly lose the exceptions that apply to natural forms.
• Which country of destination? The situation differs considerably. Austria works with a structural clause, other states with substance lists — same product, different outcomes.

What we stock instead

After this experience we have restricted ourselves to a range that does not depend on the next regulation.

Our range consists entirely of CBD products from EU-certified cultivation: CBD flowers as well as the rest of the B2B range. Every batch comes with a certificate of analysis, and the goods are marketable in the markets we deliver them to.

Why this article no longer says what it once said

Until September 2026 an advertising text for HHC and THCP wholesale stood at this address. It dated from a time when both substances were traded, and after the range was cleaned up it inadvertently remained in place. We have replaced it with this assessment instead of deleting the page — the question behind it is legitimate, the old answer no longer was.

Information as at 30 September 2026. Legal situations change; this page is an assessment and does not replace legal advice.